Vizsgálati helyszín
Ziv Medical Center
Safed, 13100, IzraelMég nincs intézményhez kötve
- 13futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis3 vizsgálat
- 1/2. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Toboroz4 vizsgálat
- Meghívásos bevonás2 vizsgálat
- Fő szponzor
- Cytokinetics4 vizsgálat
- Janssen Research & Development, LLC4 vizsgálat
- Agios Pharmaceuticals, Inc.2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- AbbVie1 vizsgálat
- és még 14
Futó vizsgálatok
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Contact: Majdi Halabi (principal investigator)
Toboroz
The Role of FAPI PET-CT in Diagnosing Endometriosis
NCT06792318· Ziv Hospital· Forrás
Contact: Israel Sandler, MD
Toboroz
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· 2/3. fázis· CSL Behring· Forrás
Contact: Trial Registration Coordinator
Fut, nem toboroz
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· 3. fázis· Cytokinetics· Forrás
Meghívásos bevonás
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993· 4. fázis· Agios Pharmaceuticals, Inc.· Forrás
Toboroz
POST URS Chemotherapy Instillation
NCT06167057· Carmel Medical Center· Forrás
Contact: Ran Katz, Dr
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555· 1/2. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780· 2/3. fázis· Agios Pharmaceuticals, Inc.· Forrás
Meghívásos bevonás
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506· 2/3. fázis· Cytokinetics· Forrás
Fut, nem toboroz
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· 3. fázis· pharmaand GmbH· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06490445· 2. fázis· Syqe Medical· Forrás
Lezárult
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· 2. fázis· Shionogi· Forrás
Lezárult
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346· 3. fázis· Cytokinetics· Forrás
Lezárult
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
NCT05514548· 2. fázis· Inversago Pharma Inc.· Forrás
Lezárult
Evaluation in STEMI Patients Using FDY-5301
NCT04837001· 3. fázis· Faraday Pharmaceuticals, Inc.· Forrás
Lezárult
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05186818· 3. fázis· Cytokinetics· Forrás
Lezárult
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
NCT04612413· 2. fázis· Enlivex Therapeutics Ltd.· Forrás
Lezárult
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· 3. fázis· AbbVie· Forrás
Lezárult
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· 3. fázis· Daiichi Sankyo· Forrás
Lezárult
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· 3. fázis· Takeda· Forrás
Lezárult
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
NCT03232073· 3. fázis· Actelion· Forrás
Hibát jelzek